Apologies, the CSL112 phase 3 trial results are not expected until Q1 CY2024, with the study fininshing late CY23.
Any $400 catalyst would be around then one would think.
And for what its worth, I read today Goldman assigned a risk adjusted value for CSL112 of 15%, up from 10% previously given some futility studies have been passed, but still very low probability of success.
From memory this opinon of low chance is due to the clinical area and past attempts by other companies in this area.
They crunched the numbers and come up with a circa $200 per share value of the RD pipeline, but risk adusted it was about $50, as in accounting for numours failures to launch.
CSL112 may well be beneficial, certainly previous studies indicate this, but it has to be clinically significant enough to bring to market. That might be the hurdle it doesn't overcome. (My comment)
- Forums
- ASX - By Stock
- Ann: CSL Notice of Research & Development Investor Briefing
Apologies, the CSL112 phase 3 trial results are not expected...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$293.00 |
Change
2.260(0.78%) |
Mkt cap ! $141.5B |
Open | High | Low | Value | Volume |
$294.00 | $294.75 | $290.82 | $491.6M | 1.702M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 8192 | $292.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$293.06 | 12368 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20 | 291.100 |
1 | 50 | 291.000 |
1 | 138 | 290.980 |
1 | 40 | 290.650 |
1 | 100 | 290.600 |
Price($) | Vol. | No. |
---|---|---|
293.060 | 209 | 1 |
293.400 | 226 | 1 |
293.500 | 10 | 1 |
293.900 | 4 | 1 |
294.000 | 695 | 5 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online